Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid Vianet Group (VNET) by Steve Moore in ShareProphets
- Avoid Kromek Group (KMK) by Steve Moore in ShareProphets
- Buy NATWEST GROUP (NWG) by Bank of America
- Buy London Stock Exchange Group (LSEG) by Bank of America
- Hold AstraZeneca (AZN) by DZ Bank
- Avoid Trifast (TRI) by Steve Moore in ShareProphets
- Buy NATWEST GROUP (NWG) by Shore Capital
- Hold Central Asia Metals (CAML) by Canaccord Genuity
- Buy Oxford Metrics (OMG) by Canaccord Genuity
- Buy Atalaya Mining (ATYM) by Canaccord Genuity
- Hold BHP Group Limited NPV (DI) (BHP) by Berenberg
- Buy Taseko Mines Limited NPV (DI) (TKO) by Canaccord Genuity
- Underperform AB Dynamics (ABDP) by Jefferies
- Buy AstraZeneca (AZN) by Stifel
- Buy QinetiQ Group (QQ.) by John Fieldsend in The Motley Fool
- Hold Antofagasta (ANTO) by Canaccord Genuity
- Hold Reckitt Benckiser Group (RKT) by Deutsche Bank
- Hold London Stock Exchange Group (LSEG) by Deutsche Bank
- Hold AstraZeneca (AZN) by Deutsche Bank
- Reduce Convatec Group (CTEC) by Peel Hunt
Nuformix (NFX) Share Price
Health Care Sector
NOTE: This is based on 8 open tips for Nuformix (NFX)
| Latest Bid : 0.18p | Latest Ask : 0.22p |
| High Today : 0.22p | Low Today : 0.18p |
| This Years High : 0.40p | This Years Low : 0.18p |
| Volume : 528 | MKT Cap : £1.56M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Nuformix (NFX) Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.Nuformix (NFX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | 13.64% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | 13.64% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | 17.39% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | 13.64% |
| Avoid | Steve Moore | Premium Only | 2022-12-13 14:00:00 13/12/2022 | 40.63% |
Nuformix (NFX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.18p | Latest Ask : 0.22p |
| High Today : 0.22p | Low Today : 0.18p |
| This Years High : 0.40p | This Years Low : 0.18p |
| Volume : 528 | MKT Cap : £1.56M |
Nuformix Overview
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. We use our expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Nuformix Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Steve Moore | Premium Only | 2023-05-25 11:25:00 25/05/2023 | 13.64% |
| Sell | Steve Moore | Premium Only | 2023-05-22 14:35:00 22/05/2023 | 13.64% |
| Sell | Steve Moore | Premium Only | 2023-05-18 14:25:00 18/05/2023 | 17.39% |
| Sell | Steve Moore | Premium Only | 2023-04-17 14:40:00 17/04/2023 | 13.64% |
| Avoid | Steve Moore | Premium Only | 2022-12-13 14:00:00 13/12/2022 | 40.63% |